)
, showing the success of the background suppression. However, no statistically significant sign of a concentration of energy deposits around the energy expected from 0νββ is apparent. The authors conclude that the half-life for 0νββ decay is greater than 1.1 × 10 25 years (at the 90% confidence level). Long lifetimes correspond to a low probability that the neutrino will flip spin, and so indicate small neutrino masses.
These results are bad news for a previous claim 2 of a positive signal for 0νββ in the decay of germanium. However, that claim had already been put under strain by earlier results 3 from EXO-200, by KamLAND-Zen (another Xe experiment in Japan based on a different technique) 4 and by the GERDA experiment 5 on double-β decay in germanium. In fact, the earlier results of EXO-200 had set the tighter lower limit on the 0νββ half-life of 1.6 × 10 25 years, and KamLAND-Zen a limit of 1.9 × 10 25 years. But in both those cases the limit was better than expected because the number of 0νββ candidate events seen was actually smaller than expected on the basis of the background events alone.
The new EXO-200 result, which is based on 3.8 times more data than its first result 3 , actually has a poorer limit, because now the researchers see a 1.2-standard-deviation excess over background in the region of the 0νββ-decay energy line -that is, they see slightly more events than their background model would predict. Such an excess of events would show up almost once every six times just from statistical fluctuations. However, as we saw with the search for the Higgs boson, a real signal would show up initially as a statistically insignificant excess. The question is whether the excess will grow with further data, and for that we must wait for more results from all the experiments. Understanding the nature of neutrinos is pivotal to models of particle physics and cosmology, so, especially now that experiments on neutrino oscillations 6 . However, because drugs that effectively treat these cancers by targeting the K-Ras protein have proved difficult to develop, the search for potential therapeutic targets has turned to the proteins that are activated downstream of this oncoprotein. In this issue, Mazur et al.
2
(page 283) identify the enzyme SMYD3 as a protein that has an unanticipated role in the progression of K-Ras-driven cancers in mice.
SMYD3, a lysine methyltransferase, is frequently overexpressed in human cancers 2, 3 . Previous work 3 has indicated that the enzyme primarily acts in the nucleus, adding methyl groups to lysine amino-acid residues on histones (proteins that organize DNA into bundles called nucleosomes). To investigate the role of SMYD3 in K-Ras-driven cancers, Mazur and colleagues used several techniques, spanning the gamut from genetically engineered mouse models to screens for SMYD3 protein substrates.
The authors found that in mouse models of K-Ras-driven cancer, SMYD3 acts in the cytoplasm of cancer cells, methylating a lysine residue (K260) on MAP3K2, a kinase enzyme that is associated 4 with the activation of several stress-induced pathways. They report that methylation of MAP3K2 potentiates a cellular signalling pathway that is involved in many human cancers 5 , the MEK-ERK mitogenactivated protein-kinase pathway. This pathway, which activates gene transcription in the nucleus, is composed of a cascade of enzymes that are sequentially activated in the presence of oncogenic K-Ras. Typically, K-Ras activates Raf; Raf activates MEK; and MEK activates ERK. Mazur and colleagues' work demonstrates for the first time that MAP3K2 can also potentiate MEK-ERK signalling downstream of oncogenic K-Ras (Fig. 1) .
The researchers show that SMYD3-mediated methylation of MAP3K2 has no direct effect on the protein's intrinsic enzymatic activity. Instead, methylation promotes dissociation of MAP3K2 from its negative regulator, the PP2A phosphatase enzyme complex. Consistent with a role for SMYD3 in tumour progression, Mazur and co-workers found that silencing of SMYD3 lengthens the median lifespan of mice that have been genetically engineered to express oncogenic K-Ras in the lungs or pancreas. Interestingly, they saw this effect only in mice with late-stage cancer progression; SMYD3 silencing did not influence tumour initiation. Strikingly, administration of a PP2A inhibitor restored tumour progression in the SMYD3-deficient mice. However, the authors did not test the effects of SMYD3 silencing in mice with aggressive cancers, which would Mutational activation of KRAS causes increased signalling through the MEK-ERK pathway, leading to cancer. In this pathway, K-Ras (which is bound by a GTP molecule) activates the kinase enzyme Raf, leading to a kinase cascade in which MEK1 and MEK2 and then ERK1 and ERK2 are activated by phosphorylation (P). ERK1 and ERK2 then activate genes involved in K-Ras-driven tumour progression. Mazur et al. report 2 that the lysine methyltransferase enzyme SMYD3 is involved in K-Ras-driven tumour progression. The enzyme acts by adding methyl groups (Me) to a lysine amino-acid residue of the kinase MAP3K2, causing it to dissociate from its negative regulator PP2A, and further activating the MEK-ERK pathway. However, it remains unclear precisely how SMYD3 and MAP3K2 are linked to K-Ras (dashed arrows).
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Enzyme meets a surprise target
An enzyme previously implicated in gene regulation has now been found to have a role in cancer progression, potentiating an intracellular signalling pathway that is driven by a mutated K-Ras protein. See Letter p.283 In sum, Mazur et al. propose that elevated SMYD3 expression promotes MAP3K2 methyl ation, freeing the protein from the inhibitory constraints of PP2A and thus potentiating signalling downstream of oncogenic K-Ras. Interestingly, methylation has previously been shown 6 to play a part in the regulation of Raf-MEK-ERK signallingmethylation of the Raf proteins B-Raf or C-Raf promotes their degradation, thereby inhibiting MEK-ERK signalling. The fact that protein methylation has now emerged as both a positive and a negative regulator of MEK-ERKpathway activation suggests that this might be a common strategy for the regulation of intracellular signalling pathways.
Mazur and colleagues' work raises the question of how SMYD3 links MAP3K2 and oncogenic K-Ras. It is unclear why SMYD3 levels are elevated in Ras-mutated cancers, such as colorectal 3 and pancreatic cancer 2 , although it is possible that Ras regulates SMYD3 expression through effects on either gene transcription or protein stability. Despite early claims 7 that MAP3K2's sister enzyme MAP3K1 can bind directly to activated Ras proteins, it seems unlikely that MAP3K2 interacts directly with oncogenic K-Ras.
Although it is well established that MEK-ERK signalling is involved in K-Ras-driven cancer, this pathway's dependence on different MAP3K enzymes (B-Raf, C-Raf and MAP3K2) is influenced by both the stage of the cancer and the tissue from which it originated 2, [8] [9] [10] . Thus, the differing effects of SMYD3 silen cing on early-and late-stage cancer progression may arise because of differing levels of MEK-ERK-pathway activation. Perhaps the activation of MAP3K2 is tied to a signalling circuit that, although not essential for the activation of MEK-ERK signalling in early-stage cancers, is required for the elevated activation of this pathway in more-advanced tumours 11 . Given the number of growth factors and other signalling molecules whose secretion is reported to be elevated in K-Ras-driven cancers [12] [13] [14] [15] [16] , oncogenic K-Ras may promote MAP3K2 activation through a feed-forward loop driven by intra-or intercellular signalling proteins, such as members of the epidermal-growth-factor family. The relationship between oncogenic K-Ras and SMYD3 is intricate and remains unclear. Moreover, at least one complication with this model is the observation that the protein kinase MKK7, a direct downstream target of MAP3K2, suppresses K-Ras-initiated lungtumour progression 17 . Might patients with late-stage K-Ras-driven lung or pancreatic cancer benefit from drugs that target SMYD3 or MAP3K2? Mazur et al. demonstrate that SMYD3 silencing slows the proliferation of human K-Ras-mutated cancer cells. Furthermore, they found that silencing of SMYD3 enhanced the antitumour effects of trametinib, a MEK-ERK-pathway inhibitor, in both cultured cells and genetically engineered mice. Importantly, mice lacking SMYD3 or MAP3K2 seem normal 2, 18 , suggesting that inhibitors of these proteins do not have severe side effects, at least in mice.
Efforts to develop drugs that inhibit SMYDfamily lysine methyltransferases or MAP3K2 are already under way 19, 20 . However, inhibition of MAP3K2 alone may not be an effective way to dampen MEK-ERK signalling because other MAP3K enzymes might be able to perform the role of MAP3K2 in its absence. Combined inhibition of SMYD3 and MAP3K2 may therefore produce more promising results.
Despite Mazur and colleagues' claims about the specificity of SMYD3 for MAP3K2, previous work 3 suggests that SMYD3 also acts as a histone modifier, regulating RNA polymerase II, the enzyme responsible for catalysing gene transcription. Thus, inhibition of SMYD3 might cause unexpected side effects. Nevertheless, the authors' work has expanded our understanding of the regulatory role of protein methylation in intracellular signalling. We must wait to see whether this regulatory mechanism can be manipulated to treat patients with K-Ras-mutated cancers. ■ 
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